Antibody drug conjugates in thoracic malignancies. (October 2018)

• Record Type: Journal Article
• Authors: Pacheco, Jose M.; Camidge, D. Ross
• Is Part Of: Lung cancer. Volume 124(2018)
• Page Start: 260
• Page End: 269
• Publication Date: 2018-10
• Subjects: Antibody drug conjugate -- Non-small-cell lung cancer -- Small-cell lung cancer -- Mesothelioma -- Thoracic malignancies; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2018.07.001
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Antibody drug conjugates may alter the efficacy: toxicity ratio of chemotherapy. Several antibody drug conjugates are being evaluated in thoracic malignancies. Available data for antibody drug conjugates in thoracic malignancies are reviewed. We discuss issues affecting efficacy and toxicity of antibody drug conjugates. Abstract: Antibody drug conjugates (ADCs) have the potential to alter the efficacy: toxicity ratio of cytotoxic therapy utilizing surface markers on cancer cells as antibody targets to preferentially deliver toxic payloads to tumor cells while limiting systemic toxicity. Multiple ADCs, differing in their antibody targets, cytotoxic payloads and linker molecules are currently being evaluated in non-small-cell lung cancer, small-cell lung cancer and malignant pleural mesothelioma. Here we review the available data in thoracic malignancies and the potential issues influencing the efficacy and toxicity of these approaches.